Homology Medicines Announces Presentations at Upcoming American Society for Gene & Cell Therapy Annual Meeting

BEDFORD, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today upcoming presentations demonstrating the broad applicability of its in vivo gene therapy and nuclease-free gene editing platform across multiple disease areas. Presentations will also include mechanistic data further characterizing Homology's novel AAVHSC vectors and details on the commercial manufacturing process and internal GMP production capabilities at Homology. These data will be presented during the virtual American Society for Gene & Cell Therapy (ASGCT) 23^rd Annual Meeting in the online poster sessions May 12 - 14, 2020.

“We are looking forward to sharing data that demonstrate the potential of our AAVHSC genetic medicines platform to treat rare genetic diseases such as PKU and MLD,” stated Albert Seymour, Ph.D., Chief Scientific Officer of Homology Medicines. “Our presentations represent how we continue to advance our understanding of Homology's proprietary AAVHSC vectors through characterization of cellular transduction, impact on cell cycle, and biodistribution to disease-relevant cell types after a single I.V. administration. Homology’s leadership in gene therapy and gene editing manufacturing will be the subject of presentations highlighting our efficient commercial process and scalable internal GMP manufacturing platform, which currently serves the needs of our clinical and preclinical programs. Additionally, our contributions to the field of gene editing will be featured in Homology data detailing molecular methods used to measure homologous recombination-based genomic integration, methods that we believe are important to characterize changes to the genome, measure integration efficiency and compare results across studies and platforms.”

Homology’s ASGCT 2020 presentations include:

In Vivo, Nuclease-Free Gene Editing for PKU
Molecular Characterization of Precise In Vivo Targeted Gene Editing in Human Cells using AAVHSC15, a New AAV Derived from Hematopoietic Stem Cells (AAVHSC)

• Tuesday, May 12; 5:30 - 6:30 p.m.
• Abstract #: 227

Scalable Manufacturing
Molecular Design and Characterization of Packaging Plasmid Sequences for Improved Production of Novel Clade F AAVHSCs

• Tuesday, May 12; 5:30 - 6:30 p.m.
• Abstract #: 445

Development and Scalability of Transfection-Based Production and Purification of Novel Clade F Adeno-Associated Viruses Isolated from Human Hematopoietic Stem Cells (AAVHSCs)